The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
Cochrane Database of Systematic Reviews 2005
DOI: 10.1002/14651858.cd002919.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
70
0
6

Year Published

2007
2007
2015
2015

Publication Types

Select...
6
3

Relationship

2
7

Authors

Journals

citations
Cited by 97 publications
(77 citation statements)
references
References 58 publications
1
70
0
6
Order By: Relevance
“…It is clear that serotonin has a role in pain mechanisms, and specifically serotonin hyper production is accompanied by tension headache and migraine pain. 18 An association exists between maternal stress and PTD. 19,20 Moreover, corticotropin-releasing hormone has been proposed as the placental clock and patients with elevated corticotropinreleasing hormone concentrations (that may results from any stress including environmental) delivered preterm.…”
Section: Discussionmentioning
confidence: 99%
“…It is clear that serotonin has a role in pain mechanisms, and specifically serotonin hyper production is accompanied by tension headache and migraine pain. 18 An association exists between maternal stress and PTD. 19,20 Moreover, corticotropin-releasing hormone has been proposed as the placental clock and patients with elevated corticotropinreleasing hormone concentrations (that may results from any stress including environmental) delivered preterm.…”
Section: Discussionmentioning
confidence: 99%
“…Meta-analysis of studies of tension type headache prophylaxis with oral treatment provide conflicting results: a lack of superiority of antidepressant medication or myorelaxants over placebo is reported in one study [53], and a beneficial effect of tricyclic antidepressants in two others [54,55]. No data are presented to evaluate a putative placebo effect.…”
Section: Prophylactic Treatment and Placebo Effectmentioning
confidence: 99%
“…No data are presented to evaluate a putative placebo effect. Interestingly, the follow-up of four groups of patients with chronic tension-type headache [54] treated with anti-depressant medication or placebo with or without stress-management therapy, showed that the placebo had a non-different effect compared to the anti-depressant medication or stress-management therapy given alone on headache activity in the sub-group with initial low CTTH severity and on disability in the sub-group without initial mood and anxiety disorders [56]. This part of the data raises the issue of the placebo efficacy in CTTH of low severity.…”
Section: Prophylactic Treatment and Placebo Effectmentioning
confidence: 99%
“…39 In migraine or tension type headache, meta-analysis has shown that SSRIs do not adequately reduce headache global severity index compared with placebo after 8 weeks of treatment. 107 Also, none of the outcome measures (main outcome measures such as headache frequency, severity, duration and secondary outcome measures such as tolerability, use of other analgesics, quality of life and mood) favored SSRIs. However, given the limitations of the available studies (small sample sizes, short follow-up duration, methodological limitations), there is a need to further investigate the effects of SSRIs in these conditions.…”
mentioning
confidence: 99%